BioNano Genomics Inc vs Figs Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Figs Inc trades at $10.13 (market cap $1.62B). The key difference: Figs Inc is far larger — about 122.7× BioNano Genomics Inc's market cap, and Figs Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FIGS | |
|---|---|---|
Market Cap | $13.20M | $1.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $17.12 |
52-Week Low | $1.09 | $5.81 |
Enterprise Value | $15.81M | $1.41B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
FIGS trades at $10.00, down 0.4% on the day, with a bearish technical signal from moving averages but recent earnings beats. The company reported Q1 2026 revenue growth of 28% and raised full-year guidance, though net cash flow remains negative. Analyst consensus is a Buy with a $19.50 price target, implying significant upside from current levels.
The outlook is mixed: strong fundamentals and growth prospects support the bull case, but valuation is rich at a P/E of 45.45, and margin pressures from tariffs and spending pose risks. The stock's performance hinges on execution of global expansion and cost management amid competitive and macroeconomic headwinds.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →